A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Phase 2 Terminated 2 enrolled Astex Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

The primary purpose of the study is to evaluate the preliminary safety and efficacy of oral decitabine/cedazuridine in combination with magrolimab.

Evaluation	Drug	Modality	Dose	Route
Subject	Cedazuridine	Small molecule	100 mg	Oral
Subject	Decitabine	Small molecule	35 mg	Oral
Subject	Magrolimab	Monoclonal antibody	30 mg/kg	Intravenous